Whitener Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.6M | Buy |
41,935
+47
| +0.1% | +$10.1K | 2.24% | 11 |
|
|
2026
Q1 | $9.11M | Buy |
41,888
+1,356
| +3% | +$301K | 2.08% | 12 |
|
|
2025
Q4 | $9.26M | Buy |
40,532
+234
| +0.6% | +$53.3K | 2.11% | 11 |
|
|
2025
Q3 | $9.33M | Buy |
40,298
+1,427
| +4% | +$291K | 2.23% | 11 |
|
|
2025
Q2 | $7.22M | Buy |
38,871
+495
| +1% | +$92K | 1.91% | 12 |
|
|
2025
Q1 | $8.04M | Buy |
38,376
+110
| +0.3% | +$21.4K | 2.28% | 11 |
|
|
2024
Q4 | $6.8M | Buy |
38,266
+309
| +0.8% | +$56.8K | 1.91% | 12 |
|
|
2024
Q3 | $7.5M | Sell |
37,957
-163
| -0.4% | -$30.4K | 2.13% | 11 |
|
|
2024
Q2 | $6.54M | Buy |
38,120
+2,766
| +8% | +$458K | 1.98% | 11 |
|
|
2024
Q1 | $6.44M | Buy |
35,354
+239
| +0.7% | +$41.2K | 2.11% | 11 |
|
|
2023
Q4 | $5.44M | Buy |
35,115
+344
| +1% | +$50.2K | 1.97% | 13 |
|
|
2023
Q3 | $5.18M | Buy |
34,771
+820
| +2% | +$120K | 2.08% | 11 |
|
|
2023
Q2 | $4.57M | Buy |
33,951
+1,101
| +3% | +$161K | 1.75% | 14 |
|
|
2023
Q1 | $5.24M | Buy |
32,850
+570
| +2% | +$87.1K | 2.19% | 11 |
|
|
2022
Q4 | $5.22M | Buy |
32,280
+42
| +0.1% | +$6.44K | 2.28% | 10 |
|
|
2022
Q3 | $4.33M | Buy |
32,238
+3,105
| +11% | +$446K | 2.05% | 10 |
|
|
2022
Q2 | $4.46M | Buy |
29,133
+1,654
| +6% | +$253K | 2.01% | 10 |
|
|
2022
Q1 | $4.45M | Buy |
27,479
+1,735
| +7% | +$252K | 1.67% | 16 |
|
|
2021
Q4 | $3.48M | Buy |
25,744
+2,263
| +10% | +$267K | 1.25% | 18 |
|
|
2021
Q3 | $2.52M | Sell |
23,481
-1,330
| -5% | -$152K | 1.16% | 20 |
|
|
2021
Q2 | $2.79M | Buy |
24,811
+1,305
| +6% | +$147K | 1.11% | 21 |
|
|
2021
Q1 | $2.54M | Buy |
23,506
+25
| +0.1% | +$2.67K | 1.1% | 21 |
|
|
2020
Q4 | $2.52M | Buy |
23,481
+446
| +2% | +$42.9K | 1.15% | 20 |
|
|
2020
Q3 | $2.02M | Buy |
23,035
+730
| +3% | +$68.7K | 0.97% | 27 |
|
|
2020
Q2 | $2.19M | Buy |
22,305
+51
| +0.2% | +$4.49K | 1.14% | 19 |
|
|
2020
Q1 | $1.7M | Buy |
22,254
+190
| +0.9% | +$16.2K | 1.1% | 22 |
|
|
2019
Q4 | $1.95M | Buy |
22,064
+1,494
| +7% | +$124K | 1.01% | 23 |
|
|
2019
Q3 | $1.56M | Buy |
20,570
+1,590
| +8% | +$109K | 0.85% | 30 |
|
|
2019
Q2 | $1.38M | Buy |
18,980
+550
| +3% | +$43.2K | 0.79% | 35 |
|
|
2019
Q1 | $1.49M | Buy |
18,430
+1,833
| +11% | +$150K | 0.97% | 21 |
|
|
2018
Q4 | $1.53M | Buy |
16,597
+1,186
| +8% | +$104K | 1.13% | 21 |
|
|
2018
Q3 | $1.46M | Buy |
15,411
+1,800
| +13% | +$171K | 0.96% | 22 |
|
|
2018
Q2 | $1.26M | Buy |
13,611
+1,326
| +11% | +$130K | 0.99% | 23 |
|
|
2018
Q1 | $1.16M | Buy |
12,285
+3,150
| +34% | +$346K | 0.89% | 25 |
|
|
2017
Q4 | $883K | Buy |
+9,135
| New | +$861K | 0.76% | 33 |
|
Other funds holding ABBV
LMFP
ATO
HCM
AAMU
FWCM
Whitener Capital Management's ABBV Position: Q2 2026 in Review
Whitener Capital Management increased its AbbVie (ABBV) stake by 0.11% in Q2 2026, buying an estimated $10.1K and bringing the position to 41,935 shares worth $10.6M. The position accounts for 2.24% of the portfolio, ranked #11.
Whitener Capital Management first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Whitener Capital Management held 41,935 shares of AbbVie worth $10.6M as of Q2 2026.
- Whitener Capital Management bought 47 AbbVie shares in Q2 2026, an estimated $10.1K.
- AbbVie made up 2.24% of Whitener Capital Management's portfolio in Q2 2026, its #11 holding.
- Whitener Capital Management first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Whitener Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.